CIBC Bancorp USA’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$480K Buy
12,605
+4,894
+63% +$206K ﹤0.01% 1389
2026
Q2
$363K Buy
+7,711
New +$191K ﹤0.01% 1443

Other funds holding DFTX

CIBC Bancorp USA's DFTX Position: Q3 2026 in Review

CIBC Bancorp USA increased its Definium Therapeutics (DFTX) stake by 63% in Q3 2026, buying an estimated $206K and bringing the position to 12,605 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #1389.

CIBC Bancorp USA first reported a position in DFTX in Q2 2026 and has held it in 2 quarters since. 292 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • CIBC Bancorp USA held 12,605 shares of Definium Therapeutics worth $480K as of Q3 2026.
  • CIBC Bancorp USA bought 4,894 Definium Therapeutics shares in Q3 2026, an estimated $206K.
  • Definium Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1389 holding.
  • CIBC Bancorp USA first reported a position in Definium Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 292 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.